Biosimilars· September 26, 2026 · 20 min read
Unbranded Biologics vs Biosimilars: Reading the Product Identity
By Ran Chen
Section
Biosimilars
Reference-product erosion, Purple Book status, interchangeability, payer switching, and specialty-channel uptake.
29 articles · Last updated
Biosimilars· September 11, 2026 · 18 min read
Biosimilar Invoice Checks: NDC, HCPCS, Package Size, and Billing Units
By Ran Chen#Biosimilars#HCPCS
Biosimilars· August 17, 2026 · 18 min read
FDA Biosimilar Device Guidance: Presentations That Are Not Interchangeable
By Ran Chen#Biosimilars#Interchangeability#Purple Book
Biosimilars· August 7, 2026 · 14 min read
Osteoporosis access landscape: Prolia's 10 denosumab biosimilars and Evenity
By Ran Chen#Biosimilars#Purple Book#Payer Policy
Biosimilars· June 29, 2026 · 18 min read
Soliris Biosimilar Cliff: NMOSD Exclusivity Expiry and Payer Step Edits
By Ran Chen#Biosimilars#Interchangeability#Payer Policy
Biosimilars· June 24, 2026 · 17 min read
Darzalex Biosimilar Tracker: SC vs IV Formulations and the 2029 Market Entry Window
By Ran Chen#Biosimilars#Purple Book#Oncology
Biosimilars· June 23, 2026 · 18 min read
Keytruda Biosimilar Tracker: The 7-Developer Race to the 2028 Cliff
By Ran Chen#Biosimilars#Oncology#FDA Approval
Biosimilars· June 22, 2026 · 20 min read
Poherdy (Pertuzumab-dpzb): FDA Approval and Payer Dynamics
By Ran Chen#Biosimilars#FDA Approval#Oncology
Biosimilars· June 21, 2026 · 6 min read
Enbrel biosimilars compared: FDA approvals, patent litigation, and the 2029 market entry
By Ran Chen#Biosimilars#FDA Approval#TNF Inhibitor
Biosimilars· June 21, 2026 · 6 min read